Executive

BARD1 has an experienced board and management team with a track record in healthcare leadership, diagnostics development and commercialisation.

Dr Leearne Hinch | Chief Executive Officer

Dr Leearne Hinch BSc, BVMS, MBA is an experienced biotechnology executive and life sciences commercialisation consultant. Leearne has a strong track record in company leadership, business strategy, fundraising, sales, business development and technology commercialisation. She has held senior executive, management and consulting positions in ASX-listed biotechnology, multinational and private companies where she led the development and commercialisation of multiple diagnostic, device, therapeutic and animal health products. Leearne holds Bachelor of Science, Bachelor of Veterinary Medicine and Surgery, and a Master of Business Administration.

Tony Di Pietro | Chief Financial Officer & Company Secretary

Tony Di Pietro B. Comm, CA, AGIA, MAICD is a Chartered Accountant with significant corporate accounting experience, gained both in Australia and the UK. He holds a Graduate Diploma of Applied Corporate Governance from the Governance Institute of Australia and is a member of the Australian Institute of Company Directors. Tony has held senior roles in the Biotechnology/ MedTech industry for the past 15 years including Sienna Cancer Diagnostics Ltd and gained valuable experience in other industry sectors at BHP Ltd, ExxonMobil Ltd, HSBC Ltd and Wilson Group.

Dr Gregory Rice | Chief Scientific Officer

Dr Greg Rice PhD BSc (Hon) MHA Grad Dip Mgt is an internationally recognised academic and commercial scientist with over 30 years’ expertise and experience in oncology, perinatology, exosome-based research, clinical translational research, IVD development and commercialisation. He has held senior academic appointments, co-founded hospital-based clinical research centres in both oncology and perinatology, and co-founded and led diagnostic companies. He is an award-winning scientist with a strong international profile and clinical research networks. He has published more than 280 peer-reviewed scientific publications and is a regular invited speaker at international conferences. He has held numerous academic leadership positions including at the University of Queensland (UQ), Baker Heart and Diabetes Institute, University of Melbourne, and Monash University. As Director of the UQ Centre for Clinical Diagnostics (CCD), he established the Centre, implemented an ISO17025 quality management system, secured NATA accreditation, and established an exosome research facility to evaluate the clinical utility of extracellular vesicles as liquid biopsies, IVDs and therapeutics. Additionally, he was a Founding Director and CSO of diagnostics company HealthLinx Ltd and more recently CEO of Pregnostica SpA. His academic qualifications include a Doctor of Philosophy and Bachelor of Science (First Class Honours) from the University of Western Australia and a Graduate Diploma in Management and Master of Health Administration from RMIT University.